UFP Technologies (UFPT) investor relations material

Leadership and organizational update

• New CEO appointed as of June 1, bringing over 30 years of experience and continuity in strategy.

• Executive Chairman role established for outgoing CEO to ensure ongoing support.

• Leadership team blends long-tenured executives with talent from recent acquisitions.

• New compensation plan ties 50% of incentives to return on invested capital and 50% to cumulative operating income over three years.

• Emphasis on shareholder-friendly governance and capital discipline.

Business model and market positioning

• Operates as a contract development and manufacturing organization (CDMO) focused on medical devices and sterile packaging.

• 2025 revenue exceeded $600 million, with a market cap of $1.7 billion and operations in six countries.

• Embedded in the design and manufacturing of products for blue-chip, niche, and startup medical device companies.

• High switching costs and long product life cycles (10–20 years) create durable customer relationships.

• Supplier partnerships provide exclusive materials and pricing advantages.

Industry trends and growth strategy

• Global medical device market exceeds $500 billion, growing at 6.3%, with outsourced spend at $100 billion growing 10%.

• Company targets 12–18% annual revenue growth, combining organic expansion and customer-centric M&A.

• Focused on innovation, scaling, and cost optimization to convert early partnerships into long-term manufacturing programs.

• M&A strategy adds new segments, customers, technologies, and geographic reach.

• Three- to five-year targets: revenue growth 12–18%, gross margins 28–31%, adjusted operating margin 17–20%.